CryoPort (NASDAQ:CYRX) Upgraded at Zacks Investment Research

CryoPort (NASDAQ:CYRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “CryoPort, Inc. operates as a provider of shipping solutions comprising cold chain frozen shipping system for transporting biological, environmental and other temperature sensitive materials at temperatures below minus 150° Celsius. Its products include CryoPort Express Shippers, cryogenic dry vapor shippers capable of maintaining cryogenic temperatures; biological material holders for the shipment of infectious or dangerous goods; CryoPort Express System to programmatically manage order entry and various aspects of shipping operations; and CryoPort Express Analytics, to monitor shipment performance metrics and to evaluate temperature-monitoring data collected by the data logger during shipment. The Company’s products find their application in the transportation of live cell pharmaceutical products, such as cancer vaccines, diagnostic materials, semen and embryos, and infectious substances. CryoPort, Inc. is based in Lake Forest, California. “

A number of other brokerages also recently issued reports on CYRX. SVB Leerink restated an “outperform” rating on shares of CryoPort in a research report on Tuesday, July 21st. Stephens boosted their price target on shares of CryoPort from $38.00 to $44.00 and gave the stock an “overweight” rating in a research report on Monday, August 24th. B. Riley boosted their price target on shares of CryoPort from $45.00 to $66.00 in a research report on Thursday, September 10th. ValuEngine upgraded shares of CryoPort from a “hold” rating to a “buy” rating in a research report on Tuesday, August 11th. Finally, TheStreet upgraded shares of CryoPort from a “d+” rating to a “c” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. CryoPort currently has a consensus rating of “Buy” and an average price target of $42.33.

NASDAQ:CYRX opened at $48.47 on Tuesday. The firm’s 50 day simple moving average is $42.61 and its 200 day simple moving average is $27.68. The company has a debt-to-equity ratio of 0.92, a current ratio of 22.95 and a quick ratio of 22.89. CryoPort has a one year low of $12.40 and a one year high of $60.82. The company has a market cap of $1.88 billion, a PE ratio of -75.73 and a beta of 1.31.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Thursday, August 6th. The consumer goods maker reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). CryoPort had a negative return on equity of 18.89% and a negative net margin of 60.97%. The business had revenue of $9.39 million for the quarter, compared to analyst estimates of $8.93 million. During the same quarter in the prior year, the business earned ($0.08) earnings per share. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. Equities research analysts expect that CryoPort will post -0.48 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its position in shares of CryoPort by 10.9% during the 1st quarter. Wells Fargo & Company MN now owns 78,937 shares of the consumer goods maker’s stock valued at $1,347,000 after acquiring an additional 7,755 shares during the period. Geode Capital Management LLC lifted its position in shares of CryoPort by 10.6% during the 1st quarter. Geode Capital Management LLC now owns 510,763 shares of the consumer goods maker’s stock valued at $8,718,000 after acquiring an additional 49,071 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of CryoPort by 13.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,963 shares of the consumer goods maker’s stock valued at $90,000 after acquiring an additional 343 shares during the period. Virtu Financial LLC acquired a new position in shares of CryoPort during the 2nd quarter valued at $249,000. Finally, Citigroup Inc. lifted its position in shares of CryoPort by 479.3% during the 1st quarter. Citigroup Inc. now owns 37,286 shares of the consumer goods maker’s stock valued at $636,000 after acquiring an additional 30,850 shares during the period. Institutional investors own 89.57% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Further Reading: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on CryoPort (CYRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.